Brief: OliX Pharmaceuticals receives patent
24/07/2018 07:05
July 24 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* Says it receives patent named treatment of age-related
macular
degeneration using rna complexes
* Says patent number is 15352322
Source text in Korean: https://goo.gl/aBcEJT
Further company coverage: 226950.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; Reuters Messaging:
Yinglan.Ma@thomsonreuters.com@reuters.net))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment